These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

649 related items for PubMed ID: 12412377

  • 1. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G, Caubel I, Belmatoug N, Billette de Villemeur T, Saudubray JM.
    Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [Abstract] [Full Text] [Related]

  • 2. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 3. [Gaucher's disease and enzyme replacement therapy].
    Cornu F.
    Ann Pharm Fr; 1998 Apr 20; 56(3):102-7. PubMed ID: 9770016
    [Abstract] [Full Text] [Related]

  • 4. [Gaucher disease: diagnosis and treatment].
    Fumić K, Stavljenić-Rukavina A, Mrsić M, Potocki K.
    Acta Med Croatica; 2004 Apr 20; 58(5):353-8. PubMed ID: 15756799
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug 20; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 6. Successful treatment of bone marrow failure in Gaucher's disease with low-dose modified glucocerebrosidase.
    Mistry PK, Davies S, Corfield A, Dixon AK, Cox TM.
    Q J Med; 1992 Jul 20; 83(303):541-6. PubMed ID: 1484931
    [Abstract] [Full Text] [Related]

  • 7. Marked clinical and histologic improvement in a patient with type-1 Gaucher's disease following long-term glucocerebroside substitution. A case report and review of current diagnosis and management.
    Heukamp LC, Schröder DW, Plassmann D, Homann J, Büttner R.
    Pathol Res Pract; 2003 Jul 20; 199(3):159-63. PubMed ID: 12812317
    [Abstract] [Full Text] [Related]

  • 8. [Gaucher's disease ].
    Belmatoug N, Caubel I, Stirnemann J, Billette de Villemeur T.
    J Soc Biol; 2002 Jul 20; 196(2):141-9. PubMed ID: 12360743
    [Abstract] [Full Text] [Related]

  • 9. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S, Roberts A, Patterson MA, Amato D.
    Blood Cells Mol Dis; 2009 Jul 20; 43(3):289-93. PubMed ID: 19793665
    [Abstract] [Full Text] [Related]

  • 10. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
    Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, Phillip M, Yaniv Y, Cohen IJ.
    Isr Med Assoc J; 2000 Feb 20; 2(2):158-63. PubMed ID: 10804944
    [Abstract] [Full Text] [Related]

  • 11. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.
    Schiffmann R, Heyes MP, Aerts JM, Dambrosia JM, Patterson MC, DeGraba T, Parker CC, Zirzow GC, Oliver K, Tedeschi G, Brady RO, Barton NW.
    Ann Neurol; 1997 Oct 20; 42(4):613-21. PubMed ID: 9382473
    [Abstract] [Full Text] [Related]

  • 12. Coagulation abnormalities in type 1 Gaucher disease in children.
    Deghady A, Marzouk I, El-Shayeb A, Wali Y.
    Pediatr Hematol Oncol; 2006 Oct 20; 23(5):411-7. PubMed ID: 16728361
    [Abstract] [Full Text] [Related]

  • 13. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
    Charrow J, Dulisse B, Grabowski GA, Weinreb NJ.
    Clin Genet; 2007 Mar 20; 71(3):205-11. PubMed ID: 17309642
    [Abstract] [Full Text] [Related]

  • 14. [Gaucher disease: clinical, genetic and therapeutic aspects].
    Germain DP.
    Pathol Biol (Paris); 2004 Jul 20; 52(6):343-50. PubMed ID: 15261378
    [Abstract] [Full Text] [Related]

  • 15. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM.
    Curr Opin Investig Drugs; 2010 Apr 20; 11(4):472-8. PubMed ID: 20336596
    [Abstract] [Full Text] [Related]

  • 16. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R.
    J Pediatr; 2007 Aug 20; 151(2):197-201. PubMed ID: 17643778
    [Abstract] [Full Text] [Related]

  • 17. Taliglucerase alfa for the treatment of Gaucher's disease.
    Haddley K.
    Drugs Today (Barc); 2012 Aug 20; 48(8):525-32. PubMed ID: 22916340
    [Abstract] [Full Text] [Related]

  • 18. [Diagnosis and therapy of Gaucher disease].
    Ehlen C, Heintges T, Niederau C.
    Med Klin (Munich); 1995 May 15; 90(5):284-90. PubMed ID: 7791695
    [Abstract] [Full Text] [Related]

  • 19. [Update on Gaucher's disease].
    Virgolini L, Silvestri F, Baccarani M.
    Minerva Med; 1993 Mar 15; 84(3):81-7. PubMed ID: 8492969
    [Abstract] [Full Text] [Related]

  • 20. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 15; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.